Topical Pentoxifylline; Metformin Versus Betamethasone in the Treatment of Alopecia Areata.
Alopecia Areata
About this trial
This is an interventional treatment trial for Alopecia Areata focused on measuring metformin, pentoxiphylline, betamethasone valerate, alopecia areata
Eligibility Criteria
Inclusion Criteria: A clinical diagnosis of patchy alopecia areata of scalp involving < 50% of the total scalp confirmed by dermoscopy of both males and females. patients age between 6 and 60 years old. Exclusion Criteria: Alopecia totalis and alopecia universalis. Cicatricial alopecia. Other causes of hair loss such as; endocrine or immunological disease. Skin disease in the affected area. Hypersensitivity or allergy to any of the treatment products used. Patient using treatment (topical or systemic) for alopecia areata in the last 2 months. Systemic administration of any of the three test drugs (pentoxifylline, metformin and steroids). Pregnant and lactating females.
Sites / Locations
- Assiut university
Arms of the Study
Arm 1
Arm 2
Arm 3
Active Comparator
Experimental
Experimental
Topical betamethasone
Topical pentoxifylline
Topical metformin
Group A will include 20 patients and will receive topical betamethasone valerate 0.1% cream. Treatment will be applied twice daily for 6 months or until complete resolution, whichever is sooner.
Group B will include 20 patients who will receive topical pentoxifylline 2% gel. Treatment will be applied twice daily for 6 months or until complete resolution, whichever is sooner.
Group C will include 20 patients who will receive topical metformin 10% gel. Treatment will be applied twice daily for 6 months or until complete resolution, whichever is sooner.